Sector News

Novo Nordisk CEO sees short-term challenges to growth – paper

December 29, 2014
Life sciences
(Reuters) – Novo Nordisk, the world’s biggest insulin maker, is confident about its long-term growth plans but needs to secure approval for its new long-acting insulin Tresiba in the United States, its chief executive said in a newspaper interview on Saturday.
 
“When we look at the long-term plan … we think that we can demonstrate growth, which is near the ten percent per year,” Chief Executive Lars Rebien Sorensen told Danish daily Berlingske. “But it gets a little challenging in the short term, for it assumes, among other things, that we get Tresiba approved in the U.S.”
 
Novo Nordisk’s once-daily insulin Tresiba, the company’s big hope for the future, failed to win U.S. approval last year.
 
“If we gets Tresiba approved in the U.S. I think we will be able to grow on average 10 percent a year over the next five years,” Sorensen said.
 
The company has delivered annual growth of around 10 percent over the last decade but challenges in the United States have increased, he said.
 
“The question is how many new generations of insulin … can be developed,” he told the newspaper.
 
Sorenson pointed to competition in diabetes treatments from rivals such as Sanofi and Eli Lilly. (Reporting by Ole Mikkelsen. Editing by Jane Merriman)

Related News

April 17, 2021

Thermo Fisher to buy research contractor PPD in $17B deal

Life sciences

Thermo Fisher Scientific plans to buy PPD for $17.4 billion to bolster its clinical research service offerings to pharmaceutical and biotech companies.

April 17, 2021

Nestlé finds supplement cocktail slashes preterm birth in major preconception study

Life sciences

Nestlé Research has linked a specific blend of myo-inositol (a type of sugar), probiotics, riboflavin, zinc and vitamins D, B6 and B12 to the decreased incidence of preterm birth when consumed before and during pregnancy.

April 17, 2021

Eli Lilly, riding pharma’s rising digital wave, drafts Apple exec to replace Shah as CDO

Life sciences

Eli Lilly hired a new digital chief from Apple in another consumer switch for pharma and as the industry speeds up its shift to online strategies.

Send this to a friend